BioNTech SE - ADR

NASDAQ:BNTX  
328.34
+15.75 (+5.04%)
4:01:30 PM EDT: $329.10 +0.76 (+0.23%)
Products, Regulatory, Earnings Announcements

Biontech Says First Patient With Advanced Melanoma Dosed In Phase 2 Clinical Trial Of MRNA-Based BNT111

Published: 06/18/2021 09:17 GMT
BioNTech SE - ADR (BNTX) - Biontech Announces First Patient Dosed in Phase 2 Clinical Trial of Mrna-based Bnt111 in Patients With Advanced Melanoma.
Biontech - First Program From Co's Fully-owned Mrna Cancer Vaccine Platform Fixvac Treats Patients in a Randomized Clinical Phase 2 Clinical Trial.
Trial is Enrolling a Total of 120 Patients at Clinical Trial Sites in European Union, United Kingdom, United States and Australia.
Phase 2 Trial is Based on Positive Results From Phase 1 Lipo-merit Trial.
Biontech-trial With Regeneron Reviewed and Approved by Authorities in Spain, Germany, Italy and Poland As Well As in United Kingdom, U.S., Australia.
Revenue is expected to be $3.82 Billion
Adjusted EPS is expected to be $8.86

Next Quarter Revenue Guidance is expected to be $3.87 Billion
Next Quarter EPS Guidance is expected to be $8.77

More details on our Analysts Page.